Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CLPP | Q16740 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13099939 | 0.88 | ADORA2A (0.37) | ADORA2AADORA1CA1CA2CA9 | |
| SCHEMBL3115250 | 0.87 | PTGS2 (0.39) | CA1CA2CA9PTGS2PDPK1 | |
| SCHEMBL3114770 | 0.87 | PTGS2 (0.39) | CA1CA2CA9PTGS2PDPK1 | |
| SCHEMBL3110282 | 0.87 | PTGS2 (0.39) | CA1CA2CA9PTGS2PDPK1 | |
| SCHEMBL3112892 | 0.87 | CA1 (0.44) | CA1CA2CA9PTGS2CA12 | |
| SCHEMBL3111507 | 0.87 | CA1 (0.43) | CA1CA2CA9PTGS2PDPK1 | |
| SCHEMBL3112965 | 0.83 | CA1 (0.39) | CA1CA2CA9PTGS2PDPK1 | |
| SCHEMBL3115566 | 0.83 | CA1 (0.35) | CA1CA2CA9PTGS2PDPK1 | |
| SCHEMBL3112977 | 0.82 | CA9 (0.49) | CA1CA2CA9PTGS2ROCK2 | |
| SCHEMBL3114696 | 0.82 | CA1 (0.41) | CA1CA2CA9PTGS2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| WO-2008017932-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | PFIZER PRODUCTS INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | ADORA2A 3337/4885ADORA1 4208/4885CA1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.